血浆游离DNA真菌PCR panel无创诊断真菌感染的临床准确性与影响
该研究开发了靶向12个常见致病真菌属/种的血浆cfDNA实时PCR panel,在IFI患者中敏感性56.5%、特异性99.5%,优化血浆量后敏感性69.6%;在226例疑似IFI患者中,20.8%检测阳性,其中42.6%对临床管理产生积极影响。
要点
- 总体敏感性56.5%,特异性99.5%,优化2 mL血浆后敏感性升至69.6%。
- 毛霉目敏感性91.7%,白念珠菌84.6%,曲霉属56.3%。
- 疑似IFI患者中20.8%阳性,42.6%阳性结果对临床管理有积极影响。
核心结论
- 真菌cfDNA PCR panel为IFI早期诊断提供无创方法,可产生指导个体化治疗的结果。
研究设计与样本
- 基于血浆样本的诊断准确性研究,IFI组115例,非IFI对照组2075例。
- 前瞻性评估226例疑似IFI患者,依据治疗团队对结果的解读评价临床影响。
主要发现
- 总体敏感性56.5%(65/115;95%CI 47.4-65.2),特异性99.5%(2064/2075;95%CI 99.0-99.7)。
- 优化血浆体积(2 mL)亚组敏感性69.6%(48/69;95%CI 57.9-79.2)。
- 毛霉目敏感性91.7%(11/12;95%CI 62.5-100),曲霉属56.3%(9/16;95%CI 33.2-76.9),白念珠菌84.6%(11/13;95%CI 56.5-96.9)。
- 226例疑似IFI患者中cfDNA检测阳性47例(20.8%),其中20/47(42.6%)对临床管理产生积极影响。
临床怎么用
- 可用于疑似IFI患者的无创早期诊断,尤其对毛霉目和念珠菌敏感性较高。
- 阳性结果可指导个体化抗真菌治疗决策,但曲霉属敏感性有限需结合其他检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal infection (IFI) is a growing cause of morbidity and mortality in oncology and transplant patients. Diagnosis of IFI is often delayed due to need for invasive biopsy and low sensitivity of conventional diagnostic methods. Fungal cell-free DNA (cfDNA) detection in plasma is a novel testing modality for the noninvasive diagnosis of IFI. METHODS: A novel bioinformatic pipeline was created to interrogate fungal genomes and identify multicopy sequences for cfDNA polymerase chain reaction (PCR) targeting. A real-time PCR panel was developed for 12 genera and species most commonly causing IFI. Sensitivity and specificity of the fungal PCR panel were determined using plasma samples from patients with IFI and non-IFI controls. Clinical impact of the fungal PCR panel was evaluated prospectively based on the treating team's interpretation of the results. RESULTS: Overall, the sensitivity and specificity were 56.5% (65/115; 95% confidence interval [CI], 47.4-65.2) and 99.5% (2064/2075; 95% CI, 99.0-99.7), respectively. In the subset of patients with an optimized plasma volume (2 mL), sensitivity was 69.6% (48/69; 95% CI, 57.9-79.2). Sensitivity was 91.7% (11/12; 95% CI, 62.5-100) for detection of Mucorales agents, 56.3% (9/16; 95% CI, 33.2-76.9) for Aspergillus species, and 84.6% (11/13; 95% CI, 56.5-96.9) for Candida albicans. In a prospective evaluation of 226 patients with suspected IFI, cfDNA testing was positive in 47 (20.8%) patients and resulted in a positive impact on clinical management in 20 of 47 (42.6%). CONCLUSIONS: The fungal cfDNA PCR panel offers a noninvasive approach to early diagnosis of IFI, providing actionable results for personalized care.
引用
- Senchyna F, Hogan CA, Murugesan K, et al. Clinical Accuracy and Impact of Plasma Cell-Free DNA Fungal Polymerase Chain Reaction Panel for Noninvasive Diagnosis of Fungal Infection. Clin Infect Dis. 2021. PMID: 33606010. doi:10.1093/cid/ciab158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。